Good morning, welcome to Repligen Corporation 2026 Annual Meeting of Shareholders. At this time, I would like to turn the meeting over to your host, Dr. Martin Madaus, Chair of the Board of Directors of Repligen. The floor is yours, Dr. Madaus.
Thank you. Good morning. It's a pleasure to welcome you to the 2026 Annual Meeting of Shareholders of Repligen Corporation. I'm Martin Madaus, the Chair of the Board of Directors of the company, and I will act as the chair of the annual meeting. In order to keep this meeting open to all shareholders, regardless of location, we are once again conducting our annual meeting virtually. As you may know, Repligen is a supplier of innovative bioprocessing tools and technologies used by leading drug developers and manufacturers.
Our customers around the globe produce many types of biotherapeutics, including monoclonal antibodies, gene and cell therapies, and vaccines. Our employees work to meet the needs of all these customers, and on behalf of the Board of Directors and our shareholders, we thank you very much for the great efforts and dedication to the company. We will now proceed to the formal portion of today's meeting. You can view the agenda for the meeting at the virtual meeting website virtualshareholdersmeetings.com/rgen2026.
There, you will find links to our meeting materials, which include our 2025 annual report, our 2026 proxy statement, and the rules of conduct for today's meetings. In order to conduct an informative, orderly, and constructive meeting we ask that participants abide by these rules. I'd like to begin with a few introductions.
Joining me today at our Waltham headquarters or virtually and representing our board directors are our President and CEO, Olivier Loeillot, Karen Dawes, Nicolas Barthelemy, Konstantin Konstantinov, Carrie Eglinton Manner, Margaret Pax, Rohin Mhatre, and Glenn Muir. Also in attendance today from Repligen is Jason Garland, our Chief Financial Officer and Corporate Secretary, George Scott, our General Counsel, Jacob Johnson, our Vice President of Investor Relations.
In addition, we are joined by Mike McCollister from Ernst & Young, Repligen's independent auditor, and Mike will be available later in the meeting if there are any questions for him from shareholders. Finally, we're joined by Terrence Hassett, our independent inspector of elections for this meeting. Terrence has signed an oath of office, which will be filed with the minutes of this meeting. Now, our sequence of events for the meeting will be as follows.
First, the polls will be opened, and each of the three matters to be voted on by the shareholders at this meeting will be presented. These matters will be presented in the order set forth in the 2026 proxy statement. We'll follow the presentation for each proposal with the opportunity for shareholders to ask questions relating to that proposal. Once all proposals have been presented, the polls will be closed, and the formal meeting will be adjourned.
You may vote at the meeting through the virtual portal by clicking on the Vote Here button, which is located at the bottom center of the screen. If you have already voted before today's meeting and you don't wish to change your vote, you don't need to vote again at the meeting. Your vote will be cast as you have previously instructed. However, if you have voted and now wish to change your vote, or if you have not voted yet and you wish to vote now, please vote during the meeting by clicking on the Vote Here button.
Meeting participants can ask a question online at any point during the meeting by typing it into the Ask a Question area located at the bottom left of the screen. If a question or comment that relates to a proposal being presented today, please submit it as soon as possible and prior to the discussion of that proposal. If you have questions that are not related to the proposals, please submit them at any time. They will be addressed, time permitting, during the question and answer session following our formal remarks.
If your question is either not addressed during the meeting or if you prefer to submit it outside of the meeting, please email our question to investors@repligen.com, and we will respond to you. Now, having reviewed the meeting logistics, we'll now proceed with the formal business of the meeting. The secretary has informed me that notice of the meeting was sent to all shareholders, off record as of close of business March 16, 2026, which is the record date of this meeting.
Only shareholders of record on that date are entitled to vote at this meeting. As of the record date, there were 56,399,274 shares of common stock outstanding and entitled to vote. Accordingly, 28,199,637 shares present at this meeting in person or represented by proxy constitute a quorum. It will be presumed, pending the final report of the Inspector of Election, that a quorum is present in order that the business of the annual meeting may be conducted. We will now proceed with the voting on the agenda items.
The polls are now open and will stay open during the discussion of the proposals and the question and answer periods. There are three matters of business to be voted on by shareholders today. These were set forth in the company's 2026 proxy statements, which was delivered to shareholders in connection with this meeting. The first matter of business is the election of nine directors, each for one-year term, which continues until 2027.
The 2027 annual meeting of shareholders and until their successors are duly elected and qualified, or until their earlier resignation or removal. As set forth in the 2026 proxy statement, Board of Directors has nominated as directors of the company our President CEO, Olivier Loeillot, Nicolas Barthelemy, Karen Dawes, Konstantin Konstantinov, Martin Madaus, Carrie Eglinton Manner, Margaret Pax, Rohin Mhatre, and Glenn Muir.
The Board of Director recommends a vote in favor of each director nominee. Do we have any questions on this item?
No, Dr. Madaus. There are no questions at this time.
Thank you. Being no questions on the proposal, the discussion is closed. If anyone is voting through the meeting website, please vote now on proposal one. The second matter of business is the ratification of the appointment of Ernst & Young as the company's independent registered public accounting firm for the fiscal year ending December 31st, 2026. The Board of Directors recommends a vote in favor of this proposal. Do we have any questions on this item?
No, Dr. Madaus, there are no questions at this time.
Thank you. There being no questions on this proposal, the discussion is closed. Anyone who's voting through the meeting website, please vote now on proposal two. The third matter of business, the non-binding advisory vote. Vote on the compensation of the company's named executive officers or say on pay. The Board of Directors recommends a vote in favor of this proposal. Do we have any questions on this item?
No, Dr. Madaus, there are no questions at this time.
There being no questions on this proposal, the discussion is closed. If anyone is voting through the meeting website, please vote now on proposal three. That concludes the voting on the proposals set forth in the 2026 proxy statement. I will pause briefly to allow shareholders to submit any votes. It's now approximately 8:00 A.M. Eastern Time, and I declare the polls closed. No further proxies or votes and no further changes or revocations will be accepted.
There being no further business to come before this formal portion of this meeting, I hereby declare the formal portion of the meeting adjourned. I'd like to thank you all for attending Repligen's Virtual 2026 Annual Shareholder Meeting and any additional questions can be sent to investors@repligen.com. Thank you and have a nice day.
Ladies and gentlemen, this concludes today's events. You may now log out of the annual meeting website. Have a good day.